Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Business & Regulation Clinical Trials, Contract Development Services, Drug Discovery

Paranoid or Prepared?

Californian firm Dynavax has signed a US$22 million agreement with the US Department of Defence (DoD) to develop a plague vaccine. Dynavax will combine its CpG 1018 adjuvant with the DoD's rF1V vaccine in a Phase II trial that will begin in 2022.

A US military spokesperson emphasized the role of this planned vaccine in defending forces abroad rather than civilians at home, speaking of a “vision to deliver a full, layered medical countermeasure capability to enable a protected and unencumbered Joint Force to fight and win in any global CBRN [chemical, biological, radiological, and nuclear] battlespace.”

Although no statement was issued regarding the source of such a challenge, it is true that both the USSR and US had active programs to weaponize plague during the cold war. The world’s governments may have good reason not to rule out the possibility of an alternative arms race...

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
Angus Stewart

Angus is Associate Editor of The Medicine Maker

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine